At the ongoing European Crohn’s and Colitis Organization (ECCO) meeting, researchers from Kangpu Biopharmaceuticals Ltd. presented efficacy data on KPG-818, a lenalidomide analogue, in a mouse model that recapitulates Crohn’s disease and ulcerative colitis.

Imidazotriazine derivatives acting as interleukin-17 (IL-17) modulators have been described in a UCB SA patent and are reported to be potentially useful for the treatment of inflammatory disorders and autoimmune diseases.

Receptor-interacting protein kinase 1 (RIPK1) regulates cell cycle and counteracts necroptosis, and is hence considered a target to watch in necroptosis-related conditions such as cancer or inflammatory diseases. Researchers from Sichuan University have reported on the discovery and structural optimization of a novel series of selective RIPK1 inhibitors intended for use in the treatment of inflammatory disorders.

AC Immune SA has identified pyrrolotriazine and imidazotriazine derivatives acting as NLRP3 inflammasome inhibitors.

NLRP3 inflammasome inhibitors have been disclosed in a Kodiak Sciences Inc. patent and described as useful for the treatment of atherosclerosis, gout, rheumatoid arthritis, inflammatory bowel, Alzheimer’s, Parkinson diseases, multiple sclerosis and glaucoma.

Synthekine Inc. has established a worldwide collaboration with Sanofi SA to develop and commercialize IL-10 receptor agonists for the treatment of inflammatory diseases.

G-protein-coupled receptor 84 (GPR84) is an orphan G protein-coupled receptor (GPCR) mainly expressed in immune cells involved in inflammation, metabolic disorders, and cancer.